Is Stem Cell Therapy Quality Control Missing Proteotoxic Cargo?

Review calls for senescence screening and EV proteomic profiling to assess whether cell therapy products can maintain protein homeostasis after transplantation

October 26, 2026
3 min

The Medicine Maker

1

The review argues that proteostatic fitness should be considered a critical quality attribute for stem cell and extracellular vesicle products.
2

Conventional release tests do not routinely assess misfolded or oxidized proteins that may accumulate during cell manufacturing.
3

Repeated ex vivo expansion can impair protein-clearance processes, while senescent cells may release inflammatory molecules and extracellular vesicles reflecting their condition.
4

In neural stem cell models, extracellular vesicles containing oxidized SOD1 were associated with mitochondrial dysfunction and secondary senescence in recipient cells.
5

The authors propose senescence screening, EV cargo profiling, and targeted release assays, but note that thresholds require harmonization and cargo sanitization needs further assessment.

Is Stem Cell Therapy Quality Control Missing Proteotoxic Cargo?

1

2

3

4

5

Original Source(s)

Is Stem Cell Therapy Quality Control Missing Proteotoxic Cargo?

Related Content

Diagnostic interpretation of CFH expression in pan-cancer analyses: the importance of factor H–like 1 isoform resolution

Genetic Link Explains Inherited Blindness

The Search for a Sepsis Signal